Scoop: ARCH’s Bob Nelsen is back­ing an mR­NA up­start that promis­es to up­end the en­tire man­u­fac­tur­ing side of the glob­al busi­ness

For the past 2 years, se­r­i­al en­tre­pre­neur Ig­or Khan­dros re­lied on a small net­work of friends and close in­sid­ers to sup­ply the first mil­lions he need­ed to fund a se­cre­tive project to mas­ter a new ap­proach to man­u­fac­tur­ing mR­NA ther­a­pies.

Right now, he says, he has a work­ing “GMP-in-a-box” pro­to­type for a new com­pa­ny he’s build­ing — af­ter launch­ing 3 pub­lic com­pa­nies — which plans to spread this con­tained, pre­cise man­u­fac­tur­ing tech around the world with a set of part­ners. He’s raised $60 mil­lion, re­cruit­ed some promi­nent ex­perts. And not co­in­ci­den­tal­ly, he’s go­ing se­mi-pub­lic with this just as a small group of pi­o­neers ap­pears to be on the thresh­old of ush­er­ing in the world’s first mR­NA vac­cines to fight a world­wide pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER